Press Releases

Date Title and Summary Additional Formats
Toggle Summary SCYNEXIS, Inc. Completes $13.5 Million Financing
Participation by Key Partner and Repeat Investor
View HTML
Toggle Summary SCYNEXIS Convenes Renowned Scientists for Symposium on the Therapeutic Promise of Cyclophilin Inhibitors View HTML
Toggle Summary SCYNEXIS to Present Preclinical HCV Data on Novel Cyclophillin Inhibitor SCY-635 at AASLD Annual Meeting View HTML
Toggle Summary SCYNEXIS and DNDi Extend Collaboration to Identify Drug Candidates to Treat Sleeping Sickness View HTML
Toggle Summary First Candidate from SCYNEXIS’ Novel Cyclophilin Inhibitor Platform, SCY 635, Establishes Proof of Concept in HCV-Infected Adults View HTML
Toggle Summary SCYNEXIS’ SCY-635 Demonstrates Clinically Relevant Single-agent Results in a Phase 1b Study in Adults with HCV
Results presented in an oral presentation at EASL; Phase 2 studies to be initiated in 2H09
View HTML
Toggle Summary SCYNEXIS and Medicines for Malaria Venture Sign HEOS® Agreement View HTML
Toggle Summary SCYNEXIS Receives Milestone Payment in Oncology Collaboration with Merck & Co., Inc. View HTML
Toggle Summary SCYNEXIS’ SCY-635 Demonstrates Positive Antiviral Activity in Combination with Approved and Investigational Anti-HCV Agents
In Vitro Results presented in a poster session at AASLD; Phase 2 combination studies to be initiated in 2Q 2010
View HTML
Toggle Summary SCYNEXIS Receives Merial Research Collaboration Milestone Payment View HTML